A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken once-weekly during the four-month continuation phase, Dr Amina Jindani of St George’s University Medical School, London, told the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, on 6 March.
However, using the same drugs twice-weekly does not permit the total TB treatment course to be reduced from six months to four months, the study found.
The RIFAQUIN study compared two strategies for either reducing the length of the TB treatment course or reducing the total number of doses.
via HIV & AIDS Information :: Once-weekly continuation phase TB treatment equals standard of care.
Dr. Amina Jindani is currently Honorary Senior Lecturer at St George’s, University of London where she is coordinating the International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis, known as INTERTB. An international trial conducted by her has led to changes in the recommendations by the World Health Organisation (WHO) for the treatment of tuberculosis.
In June 2003, she was elected as a Fellow of the Royal College of Physicians of London.
Dr. Amina Jindani’s post-doctoral thesis was based on the early bactericidal activity of tuberculosis drugs on the rate of reduction of the bacterial load in the sputum. This method is now applied in the evaluation of new drugs for tuberculosis.
She has been involved with clinical trials of tuberculosis since the 1960s when she coordinated the first East African/British Medical Research Council trial of short-course chemotherapy in Africa.
She was awarded a Bachelor’s degree from the University of London, accompanied by special awards in Paediatrics and Pharmacology and membership of the Royal College of Physicians of the United Kingdom.
http://www.sgul.ac.uk/research/researchers/g-k/amina-jindani
Ismailimail 